Slide 1: First Quarter Fiscal Year 2025 Earnings Presentation
AngioDynamics First Quarter Fiscal Year 2025 Earnings Presentation October 3, 2024
Slide 2: Forward-Looking Statements
Forward-Looking Statements Notice Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations,
Slide 3: FY Q1 2025 Key Takeaways
FY Q1 2025 Key Takeaways Continued commercial and operational execution positions AngioDynamics to drive accelerated, profitable growth moving forward CONTINUED COMMERCIAL EXECUTION • +1.1% YoY pro forma revenue growth • MedTech segment pro forma revenue growth of 8.7% YoY • Auryon sales of $13.7 mi
Slide 4: Q1 FY 2025 Pro Forma Financial Snapshot
Q1 FY 2025 Pro Forma Financial Snapshot Net Sales Segment Revenue Contribution Q1 24 Q1 25 $66.7 $67.5 39% +8.7% 41% $25.7 $28.0 Pro Forma Growth 59% 61% Med Device Med Tech Med Device Med Tech (3.6)% $41.0 $39.5 Pro Forma Growth Segment Gross Margin Q1 24 Q1 25 48.2% 63.3% Med Device Med Tech Med D
Slide 5: Med Tech - Auryon
Med Tech - Auryon Period Sales YoY Growth Q1 2025 $13.7M 24.9% • Cumulative sales of over $140M since launch in Sept 2020 • Launched Auryon XL Radial Catheter in FY24 • Launched 1.7mm Catheter in Q1 FY25 • European CE Mark approval in Q1 FY25 5
Slide 6: Med Tech - Thrombus Management
Med Tech - Thrombus Management 1Q 2025 Sales YoY Growth AngioVac $5.8M (8.0%) AlphaVac $2.2M 21.1% Total Mech Thromb. $8.0M (1.6%) Unifuse $1.2 1.3% Total Thrombus Mgmt. $9.2 (1.3%) AlphaVac • Completed APEX-AV IDE study in Pulmonary Embolism (PE) in Q3 FY24 • Received FDA 510(k) & CE Mark for PE in
Slide 7: Med Tech - NanoKnife
Med Tech - NanoKnife 1Q 2025 Sales YoY Growth Disposables $4.1M (4.6)% Capital $1.0M (15.0)% Total $5.1M (6.9)% • Completed enrollment of PRESERVE trial in July of 2023, designed to prove that NanoKnife is a safe and effective treatment for men diagnosed with intermediate risk prostate cancer • Comp
Slide 8: Med Device
Med Device 1Q 2025 Sales YoY Growth Core Peripheral $18.4M (0.9%) Venous / EVLT $6.1M 0.5% Ports $9.4M 4.5% Solero Microwave $4.1M (27.1%) Alatus and Isoloc Balloons $1.1M (11.6%) Other Med Device $0.4M (16.8%) Total $39.5M (3.6)% 8
Slide 9: Fiscal Year 2025 Guidance
Fiscal Year 2025 Guidance Reiterated all guidance components introduced on July 16, 2024 Metric Guidance Full Year Net Sales $282 - $288 million Med Tech Net Sales 10 – 12% YoY growth Med Device Net Sales 1 – 3% YoY growth Gross Margin 52 - 53% Adjusted EBITDA ($2.5) - $0 million Adjusted EPS ($0.38
Slide 10: Fiscal Year 2025 Catalysts
Fiscal Year 2025 Catalysts Auryon • Received CE Mark in Q1 FY2025 • Conducting limited market release in EU before transitioning to full market release • Continuing to increase penetration in the hospital setting in the U.S. AlphaVac • Executing full commercial launch of PE indication in U.S. and CE
Slide 11: Appendix
Appendix 11
Slide 12: Reconciliation of GAAP to Non-GAAP Pro Forma Results for the Consolidated Income Statements
Reconciliation of GAAP to Non-GAAP Pro Forma Results for the Consolidated Income Statements (in thousands, except per share data) 12
Slide 13: Reconciliation of GAAP to Non-GAAP Adjusted Net Loss and EPS
Reconciliation of GAAP to Non-GAAP Reconciliation of Net Loss to Adjusted Adjusted Net Loss and EPS EBITDA (in thousands, except per share data) (in thousands, except per share data) 13
Slide 14: Reconciliation of Non-GAAP Pro Forma Net Loss to Adjusted Pro Forma Net Loss and EBITDA
Reconciliation of Non-GAAP Pro Forma Reconciliation of Non-GAAP Pro Forma Net Loss to Adjusted Pro Forma Net Loss Net Loss to Adjusted Pro Forma EBITDA and EPS (in thousands, except per share data) (in thousands, except per share data) 14
Slide 15: Detail of Acquisition, Restructuring and Other Items, net
Detail of “Acquisition, Restructuring and Other Items, net” 15
Slide 16: Reconciliation of GAAP to Non-GAAP Pro Forma Results for Sales and Gross Margin by Product Category
Reconciliation of GAAP to Non-GAAP Pro Forma Results for Sales and Gross Margin by Product Category (in thousands) 16